Earnings call transcript: Teva's Q2 2025 shows steady growth, stock rises
PositiveFinancial Markets
Teva Pharmaceuticals reported steady growth in its Q2 2025 earnings call, leading to a rise in its stock price. This positive performance highlights the company's resilience and strategic initiatives in a competitive market, which is encouraging for investors and stakeholders alike.
— Curated by the World Pulse Now AI Editorial System













